<DOC>
	<DOCNO>NCT01137682</DOCNO>
	<brief_summary>This study evaluate efficacy safety pasireotide LAR 40 60 mg versus octreotide LAR lanreotide ATG patient inadequately control acromegaly .</brief_summary>
	<brief_title>Efficacy Safety Pasireotide Long Acting Release ( LAR ) Versus Octreotide LAR Lanreotide Autogel ( ATG ) Patients With Inadequately Controlled Acromegaly</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>1 . Patients write informed consent prior study related activity 2 . Patients inadequately control acromegaly define mean GH concentration 5point profile 2hour period &gt; 2.5 Âµg/L sex ageadjusted IGF1 &gt; 1.3 x upper limit normal ( ULN ) 3 . Patients treat maximum indicated dos octreotide LAR lanreotide ATG least 6 month prior visit 1 ( screen ) . The maximum indicated dose octreotide LAR 30mg lanreotide ATG 120 mg 4 . Patients diagnosis pituitary micro macro adenoma . Patients previously submit surgery 1 . Patients receive pasireotide ( SOM 230 ) prior enrolment 2 . Concomitant treatment Growth Hormone Receptor ( GHR ) antagonist dopamine agonist unless concomitant treatment discontinue 8 week prior visit 1 ( screen ) ( 8 week wash period ) . Such patient must treat octreotide LAR 30 mg lanreotide ATG 120 mg monotherapy continuously minimum 6 month prior start combination therapy inadequately control monotherapy . 3 . Patients compression optic chiasm cause acute clinically significant visual field defect 4 . Patients require surgical intervention relief sign symptom associate tumor compression 5 . Patients receive pituitary irradiation within 10 year prior visit 1 ( screen ) . 6 . Patients undergone major surgery/surgical therapy cause within 4 week prior visit 1 ( screen ) . 7 . Patients hypothyroid adequately treat stable dose thyroid hormone replacement therapy Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Acromegaly</keyword>
	<keyword>hormone disorder</keyword>
	<keyword>growth hormone</keyword>
	<keyword>insulin like growth factor-1</keyword>
	<keyword>pituitary tumor</keyword>
</DOC>